Your browser doesn't support javascript.
loading
Efficacy and safety of chitosan-based bio-compatible dressing versus nanosilver (ActicoatTM ) dressing in treatment of recalcitrant diabetic wounds: A randomized clinical trial.
Abdollahimajd, Fahimeh; Pourani, Mohammad Reza; Mahdavi, Hamid; Mirzadeh, Hamid; Younespour, Shima; Moravvej, Hamideh.
Afiliación
  • Abdollahimajd F; Department of Dermatology, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Pourani MR; Clinical Research Development Unit of Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mahdavi H; Department of Dermatology, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mirzadeh H; Novel Drug Delivery Systems Department, Polymer Science Faculty, Iran Polymer and Petrochemical Institute, Tehran, Iran.
  • Younespour S; Department of Polymer Engineering, Amirkabir University of Technology, Tehran, Iran.
  • Moravvej H; Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Dermatol Ther ; 35(9): e15682, 2022 09.
Article en En | MEDLINE | ID: mdl-35778935
Chitosan has a biocompatible, biodegradable, and nontoxic nature. The effectiveness of Nano-chitosan films in the field of wound healing has been confirmed previously. The aim of this study was to compare the clinical efficacy and safety of two dressings (chitosan and nanosilver dressings) in the treatment of refractory diabetic wounds. A total of 25 eligible patients with chronic diabetic wound were included and randomly assigned to receive chitosan (13 patients) or nanosilver (12 cases) dressing. The dressings were applied on the wounds based on their protocols and patients were visited and examined by an experienced dermatologist every week. The clinical assessments and healing rates were recorded using diabetic-foot-infection (DFI) score at the 2nd, 4th, and 6th weeks during treatment. The study endpoint, safety and tolerability profile were also documented. The patterns of change in total 10-item-DFI wound scores did not differ significantly over time between the two groups. In both groups, the total 10-item-DFI wound score reduced continuously through the course of study. The mean percentage reduction of this score from baseline was 78.1% and 74.1% in the chitosan and nanosilver dressing groups, respectively. Both dressings were well tolerated and there were no adverse events. The relatively small sample size in both groups was the main limitation of the study. Our findings confirmed that chitosan may be safely and effectively used for the treatment of diabetic wounds just like the nanosilver (ActicoatTM ) dressing. Further studies are recommended with more volunteers and a longer follow-up period.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quitosano / Diabetes Mellitus Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quitosano / Diabetes Mellitus Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos